This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Incyte (INCY) and Incannex Healthcare Limited Sponsored ADR (IXHL)

Tipranks - Tipranks - Fri Jun 12, 8:28AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clover Health Investments (CLOV), Incyte (INCY) and Incannex Healthcare Limited Sponsored ADR (IXHL).

Introducing TipRanks MCP for Agents

Clover Health Investments (CLOV)

In a report released today, Jonathan Yong from UBS maintained a Hold rating on Clover Health Investments, with a price target of $4.75. The company’s shares closed last Wednesday at $4.89.

Yong has an average return of 24.9% when recommending Clover Health Investments. ;'>

According to TipRanks.com, Yong is ranked #2946 out of 12286 analysts.

Clover Health Investments has an analyst consensus of Moderate Buy, with a price target consensus of $4.48, a -1.8% downside from current levels. In a report issued on May 29, TipRanks – DeepSeek also downgraded the stock to Hold with a $4.50 price target.

See today’s best-performing stocks on TipRanks >>

Incyte (INCY)

Guggenheim analyst Michael Schmidt maintained a Buy rating on Incyte on June 8 and set a price target of $130.00. The company’s shares closed last Wednesday at $105.39.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 26.7% and a 51.9% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, ArriVent BioPharma, Inc., and Monte Rosa Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.38 average price target, a 6.8% upside from current levels. In a report issued on June 8, TipRanks – Anthropic also upgraded the stock to Buy with a $114.00 price target.

Incannex Healthcare Limited Sponsored ADR (IXHL)

Alliance Global Partners analyst James Molloy initiated coverage with a Buy rating on Incannex Healthcare Limited Sponsored ADR on June 8 and set a price target of $18.00. The company’s shares closed last Wednesday at $3.91.

According to TipRanks.com, Molloy has 0 stars on 0-5 stars ranking scale with an average return of -22.5% and a 23.2% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Intensity Therapeutics, Inc., and SELLAS Life Sciences Group. ;'>

Currently, the analyst consensus on Incannex Healthcare Limited Sponsored ADR is a Moderate Buy with an average price target of $18.00.

Read More on CLOV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).